Chemical Compound
N-Trifluoroacetyladriamycin
CAS Registry Number
26295-56-7
Primary Record
N-Trifluoroacetyladriamycin
- In stock
- 7,879 g
- Purity
- 99.3 %
- CAS
- 26295-56-7
Compound Identifiers & Properties
- CAS
- 26295-56-7
- PubChem CID
- 73551
- SMILES
- C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)NC(=O)C(F)(F)F)O
- Canonical SMILES
- COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1
Names & Synonyms
- N-Trifluoroacetyladriamycin
- N-Trifluoroacetyldoxorubicin
- ITA96UBK4T
- RefChem:927350
- UNII-ITA96UBK4T
- AD-41
- AC1L2K2G
- N-Trifluoroacetyl Doxorubicin
- N-(Trifluoroacetyl)doxorubicin
- 26295-56-7
- DTXSID10949158
- RQIOYWADAKTIJC-XUKKXQNXSA-N
- AD 41
- AD41
- orb1701851
- SCHEMBL22566387
- SCHEMBL29395359
- C29H28F3NO12
- DTXCID501768824
- KST-1A3344
- NSC 283464
- NSC-283464
- CID73551
- BRN 1417667
- AR-1A1601
- NSC283464
- ZINC95618916
- AKOS040747228
- C29-H28-F3-N-O12
- C37H50N2O6S.2ClH.2/3C3H8O
- J85.474C
- LS-94123
- CS-0108244
- C37-H50-N2-O6-S.2Cl-H.2/3C3-H8-O
- Q27280887
- 27124-11-4
- Emetine, 2'-(3-(furfurylthio)-2-hydroxypropyl)-, dihydrochloride
- (1s,3s)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 2,3,6-trideoxy-3-[(trifluoroacetyl)amino]-|A-l-lyxo-hexopyranoside
- 2,2,2-trifluoro-N-[(2S,3S,4S,6R)-3-hydroxy-2-methyl-6-[[(1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]oxan-4-yl]acetamide
- 3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl 2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-L-lyxo-Hexopyranoside (1S,3S)- alpha-
- 2-Propanol, 1-((2-furanylmethyl)thio)-3-(6',7',10,11-tetramethoxyemetan-2'-yl)-, 2HCl
- (1S,3S)-3,5,12-Trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranoside
- (8S)-1-Methoxy-6,8alpha,11-trihydroxy-8-(hydroxyacetyl)-10alpha-[[3-(trifluoroacetylamino)-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-5,12-naphthacenedione
- (8S,10S)-7,8,9,10-Tetrahydro-8-(hydroxyacetyl)-1-methoxy-10-[[3-(trifluoroacetylamino)-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl]oxy]-6,8,11-trihydroxy-5,12-naphthacenedione
- 2,2,2-trifluoro-N-[(2S,3S,4S,6R)-3-hydroxy-2-methyl-6-[[(1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]tetrahydropyran-4-yl]acetamide
- 2,2,2-trifluoro-N-[(2S,3S,4S,6R)-3-hydroxy-2-methyl-6-{[(1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl]oxy}oxan-4-yl]acetamide
- 2H-Benzo(a)quinolizine, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2-((1,2,3,4-tetrahydro-6,7-dimethoxy-2-(3-(2-furylmethylthio)-3-hydroxypropyl)-1-isoquinolyl)methyl)-, dihydrochloride, isopropanol (3:6:2)
- 5,12-NAPHTHACENEDIONE, 7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-8-(2-HYDROXYACETYL)-1-METHOXY-10-((2,3,6-TRIDEOXY-3-((2,2,2-TRIFLUOROACETYL)AMINO)-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-, (8S,10S)-
- 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[(trifluoroacetyl)amino]-.alpha.-L-lyxo-hexopyranosyl]oxy]-, (8S-cis)-
- 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-8-(hydroxyacetyl)-1-methoxy-10-((2,3,6-trideoxy-3-(trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-6,8,11-trihydroxy-, (8S-cis)-
- L-Lyxo-exopyranoside, 3-glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl-2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-, (1S,3S)-.alpha.-
- L-lyxo-Hexopyranoside, 3-glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl 2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-, (1S,3S)- alpha-
- L-lyxo-Hexopyranoside, 3-glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl-2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-, (1S,3S)- alpha-